

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY OWNED SUBSIDIARY

Reference is made to the announcement dated 30 December 2025 (the “**Announcement**”) issued by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) regarding Changchun Extrawell, a 80.46% indirect non-wholly owned subsidiary of the Company, entered into the Share Buy-Back Agreement with the Vendor to buy back for cancellation 10.06% of total issued share capital of Changchun Extrawell. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that all the Conditions have been fulfilled and the Completion of Share Buy-Back and Share Cancellation has been taken place on 16 March 2026. Immediately upon Completion and as at the date of this announcement, the total number of issued shares of Changchun Extrawell has reduced from 45,430,000 shares to 40,860,000 shares, and as a result of Share Cancellation, Changchun Extrawell’s registered capital has reduced from RMB45,430,000 to RMB40,860,000 and the Group’s equity interest in Changchun Extrawell is increased from 80.46% to 89.46%. After Completion, Changchun Extrawell will be owned by the Company (indirectly through Extrawell Enterprises), Shareholder A, Shareholder B and Shareholder C as to 89.46%, 4.48%, 3.82% and 2.24% respectively. Changchun Extrawell remains an indirect non-wholly owned subsidiary of the Group and accordingly the financial results (including earnings, assets and liabilities) of Changchun Extrawell will be consolidated into the financial statements of the Group.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 17 March 2026

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Guo Yi, Mr. Cheng Yong, Dr. Lou Yi and Ms. Wong Sau Kuen, and the independent non-executive directors are Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong.

* *For identification purpose only*